Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Parkinson’s disease (PD) is a progressive, neurodegenerative disorder with cardinal motor features of tremor, bradykinesia, and rigidity. This disease affects more than 1.5 million Americans older than 50 years of age with the incidence increased significantly with age. Despite advances in treatments over the years, there is no cure for Parkinson’s. Symptomatic therapy can provide benefit for quite some time, but slow progression eventually results in significant disability. PD is characterized by a striatal dopamine deficiency. The degeneration of dopamine-containing neurons in the substantia nigra leads to the formation of Lewy bodies – intracellular neuronal inclusion bodies. A major treatment breakthrough was the replacement of dopamine in the brain by using levodopa. Although it provides benefit to nearly all PD patients, long-term use of levodopa is complicated by the development of motor fluctuations, dyskinesias, and neuropsychiatric complications.

Dopamine agonists are often used as initial therapy in early PD. These agents have a levodopa-sparing effect and can reduce the frequency of off-periods. These agents are also FDA approved to treat Restless Leg Syndrome (RLS), where patients experience irresistible sensations in the legs or arms while sitting or lying still.

Total program savings for the PDL classes will be regularly reviewed.

<table>
<thead>
<tr>
<th>Program-Specific Information:</th>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amantadine</td>
<td>Apokyn®</td>
</tr>
<tr>
<td></td>
<td>Pramipexole</td>
<td>Gocovri®</td>
</tr>
<tr>
<td></td>
<td>Ropinirole</td>
<td>Mirapex®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mirapex ER®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neupro®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Osmolex™ ER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pramipexole ER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Requip®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Requip XL®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ropinirole ER</td>
</tr>
</tbody>
</table>
Type of Criteria:  ☐ Increased risk of ADE  ☒ Preferred Drug List
☐ Appropriate Indications  ☐ Clinical Edit

Data Sources:  ☐ Only Administrative Databases  ☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Anti-Parkinsonism Non-Ergot Dopamine Agonists
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
  - Documented trial period for preferred agents
  - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

Required Documentation

- Laboratory Results:  
- Progress Notes:  
- MedWatch Form:  
- Other:

Disposition of Edit

- Denial: Exception Code “0160” (Preferred Drug List Edit)
- Rule Type: PDL

Default Approval Period

1 year

References

4. USPDI, Micromedex; 2019.